Related Experiment Video

Updated: Aug 20, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

[Plasma volume in polycystic kidney disease]

M Merta1, V Chábová, V Tesar

  • 1I. interní klinika, lékarská fakulta Univerzity Karlovy, Praha.

Sbornik Lekarsky
|January 1, 1994
PubMed

Insights

Hypertension in autosomal dominant polycystic kidney disease (ADPKD) is not linked to increased plasma and blood volume (PV and BV) early on. This study found no significant PV or BV changes before hypertension onset in ADPKD patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Genetics

Context:

  • Autosomal dominant polycystic kidney disease (ADPKD) frequently leads to early-onset hypertension.
  • Sodium transport disorders and volume expansion are hypothesized contributors to ADPKD hypertension.
  • Understanding early volume status is crucial for managing ADPKD complications.

Purpose:

  • To investigate plasma volume (PV) and blood volume (BV) in patients with early-stage ADPKD.
  • To determine if increased PV and BV precede or contribute to hypertension in ADPKD.
  • To compare volume status between hypertensive ADPKD, normotensive ADPKD, and healthy individuals.

Summary:

  • Plasma volume (PV) and blood volume (BV) were measured using radioactive serum albumin dilution in three groups: ADPKD hypertensive, ADPKD normotensive, and healthy controls, all with normal glomerular filtration rate.
  • When normalized for body surface area, a diminished blood volume (BV) was observed in the hypertensive ADPKD group compared to normotensive ADPKD patients and controls (p < 0.05).
  • No significant differences in PV or BV were found when expressed per kilogram of body weight, and other parameters did not differ between groups.

Impact:

  • The findings challenge the prevailing hypothesis that increased plasma and blood volume are key drivers of hypertension in early ADPKD.
  • Suggests that other pathophysiological mechanisms may be more significant in the development of hypertension in ADPKD.
  • Provides valuable data for refining therapeutic strategies targeting volume regulation in ADPKD patients.

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys08:21

Use of 3D Robotic Ultrasound for In Vivo Analysis of Mouse Kidneys

Published on: August 12, 2021

Related Concept Videos

Nephrons01:10

Nephrons

The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma happens...
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels01:31

Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels

Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted less...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...